Register Login

Akero Therapeutics (AKRO)

  • Event
  • Aug. 04, 2022, 20:17 UTC

(75% Positive) Akero Therapeutics, Inc. (AKRO) Announces Enrollment Update for results Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 6:55 p.m.

    📋 Akero Therapeutics, Inc. (AKRO) - Clinical Trial Update

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 16:17:35

    Event Type: Clinical Trial Update

    Event Details:

    Akero Therapeutics (AKRO) Announces Clinical Trial Update Akero Therapeutics (AKRO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, risk
    • Collaboration: Akero
      • Akero announced a $25 million equity investment from Pfizer Inc. and up to a $100 million term loan facility through Hercules Capital, Inc., to support continued development of EFX, Akero’s lead product candidate.
      • Akero presented an analysis at the 2022 International Liver Congress demonstrating the potential for EFX to treat patients at the highest genetic risk for progressive NASH and end
      • stage liver disease, including hepatocellular carcinoma. Data showed that EFX improved histopathology and noninvasive markers of liver injury to a similar extent in patients carrying the highest risk PNPLA3 genotype as patients who were not carriers.

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Akero Therapeutics
    • CIK: 0001744659
    • Ticker Symbol: AKRO
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories